**Question:** NRTI which has maximum tendency to cause peripheral neuropathy

**Core Concept:** NRTIs (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors) are a class of antiretroviral drugs used in the treatment of HIV infection. Peripheral neuropathy is a common side effect of NRTIs, affecting the nerves in the limbs.

**Why the Correct Answer is Right:** The correct answer, D4T (Stavudine), is known for its high propensity to cause peripheral neuropathy compared to other NRTIs. D4T is a thymidine analogue that competes with endogenous thymidine for incorporation into the DNA of HIV, preventing reverse transcription and inhibiting HIV replication. However, D4T can cause high levels of intracellular dThdP triphosphate, leading to increased DNA chain termination and production of abnormally long DNA fragments. This process, known as "DNA chain termination syndrome," results in the development of peripheral neuropathy.

**Why Each Wrong Option is Incorrect:**

A. AZT (Zidovudine): AZT is also an NRTI but is less likely to cause peripheral neuropathy compared to D4T due to its lower propensity to produce DNA chain termination syndrome.

B. ZDV (Zalcitabine): Zalcitabine is another NRTI with lower potential for causing peripheral neuropathy than D4T due to differences in pharmacokinetic properties and toxicity profiles.

C. Didanosine (ddI): Didanosine is another NRTI with lower risk of peripheral neuropathy compared to D4T, as it is less likely to cause DNA chain termination and produce neurotoxicity.

**Core Concept (for reference):** DNA chain termination syndrome is a process in which NRTIs cause excessive DNA chain termination, resulting in abnormally long DNA fragments and ultimately leading to peripheral neuropathy.

**Core Concept (for reference):** Peripheral neuropathy is a side effect of NRTIs due to their interference with normal neuronal function and can manifest as pain, tingling, numbness, or muscle weakness in the extremities.

**Core Concept (for reference):** DNA chain termination syndrome is a term used to describe the toxic effect of NRTIs on DNA replication, leading to the production of abnormally long DNA fragments and subsequent neuronal dysfunction causing peripheral neuropathy.

**Why Each Wrong Option is Incorrect:**

Option A (AZT) and Option C (Didanosine) are less likely to cause peripheral neuropathy due to their lower propensity to produce DNA chain termination syndrome and neuronal dysfunction.

Option B (Zalcitabine) and Option D (Stavudine) are also less likely to cause peripheral neuropathy compared to D4T due to differences in pharmacokinetic properties and toxicity profiles. These agents have lower propensity to accumulate in peripheral nerves and cause neuronal dysfunction, resulting in neuropathy.

**Core Concept (for reference):** Pharmacokinetic properties refer to the properties of a drug that determine its distribution, absorption, and elimination from the body, which can affect the severity of side effects.

**